Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor

Shih Hwa Chiou*, Chung Lan Kao, Yi Wei Chen, Chien Shu Chien, Shih Chieh Hung, Jeng Fan Lo, Yann Jang Chen, Hung Hai Ku, Ming Ta Hsu, Tai Tong Wong

*此作品的通信作者

研究成果: Article同行評審

105 引文 斯高帕斯(Scopus)

摘要

Atypical teratoid/rhabdoid tumor (AT/RT) is an extremely malignant neoplasm in the central nervous system (CNS) which occurs in infancy and childhood. Recent studies suggested that CD133 could be considered a marker for brain cancer stem-like cells (CSCs). However, the role of CD133 in AT/RT has never been investigated. Herein we report the isolation of CD133-positive cells (CD133+), found to have the potential to differentiate into three germ layer tissues, from tissues of nine AT/ RT patients. The migration/invasion/malignancy and radioresistant capabilities of CD133+ were significantly augmented when compared to CD133. The clinical data showed that the amount of CD133+ in AT/RTs correlated positively with the degree of resistance to radiation therapy. Using cDNA microarray analysis, the genotoxic-response profiles of CD133+ and CD133- irradiated with 10 Gy ionizing radiation (IR) were analyzed 0.5, 2, 6, 12, and 24 h post-IR. We then validated these microarray data and showed increased phosphorylation after IR of p-ATM, p-RAD17, and p-CHX2 as well as increased expression of BCL-2 protein in CD133+ compared to CD133. Furthermore, we found that CD133+ can effectively resist IR with cisplatin- and/or TRAIL-induced apoptosis. Immunohistochemical analysis confirmed the up-regulated expression of p-ATM and BCL-2 proteins in IR-radiated CD133+ xenografts in SCID mice but not in IR-treated CD133-. Importantly, the effect of IR in CD133+ transplanted mice can be significantly improved by a combination of BCL-2 siRNA with debromohymenialdisine, an inhibitor of checkpoint kinases. In sum, this is the first report indicating that CD133+ AT/RT cells demonstrate the characteristics of CSCs. The IR-resistant and anti-apoptotic properties in CD133+ may reflect the clinical refractory malignancy of AT/RTs and thus the activated p-ATM pathway and BCL-2 expression in CD133+ could be possible targets to improve future treatment of deadly diseases like AT/RT.

原文English
文章編號e2090
期刊PLoS ONE
3
發行號5
DOIs
出版狀態Published - 7 5月 2008

指紋

深入研究「Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor」主題。共同形成了獨特的指紋。

引用此